Debra Ann Peattie

57635900, Jun 9, 1998

Nov 9, 1994

8/336618

Debra A. Peattie - Cambridge MA
Matthew W. Harding - Acton MA
David J. Livingston - Newtonville MA

Vertex Pharmaceuticals, Inc. - Cambridge MA

C12N 1512

536 235

An FK506 binding protein of mammalian origin of approximate size (M. sub. r) 52,000, isolated by FK506 affinity chromatography and a corresponding human cDNA of approximate size 2. 2 Kb, isolated by screening a human placenta cDNA library with a DNA probe whose sequence predicts a consensus amino acid sequence present in five FKBP12 sequences and in the human FKBP13 sequence.

20190083518, Mar 21, 2019

Sep 20, 2018

16/136787

- Lincoln MA, US
Debra A. Peattie - Lincoln MA, US

A61K 31/7048
A61K 45/06
A61K 9/127
A61K 9/107
A61K 9/00
A61K 9/51
A61P 11/02
A61P 11/06
A61P 11/12
A61P 11/08
A61P 31/16

Disclosed are compositions and methods for treating, amelioriating, reversing and/or preventing (acting as a prophylaxis): a respiratory condition involving an infection or an inflammation, or any lung condition involving inflammation or infection, e.g., of a respiratory mucosa, and/or an infection or an inflammation of an underlying muscle of the respiratory tract; or, an asthma; a bronchitis; a sinusitis or rhinosinusitis; an infection of a sinus; chronic obstructive airway disease; emphysema; chronic bronchitis; pneumonia; or, a bronchiectasis. In alternative embodiments, the therapeutic combination comprises an orally administered Amphotericin B or equivalent antifungal alone, or a combination of Amphotericin B and: one antibiotic; two antibiotics; three antibiotics; or, four or more antibiotics. In alternative embodiments, these compositions and methods are dosaged and administered to children in need thereof. In alternative embodiments, compositions and methods of the invention are dosaged, formulated and dosaged as tablet, capsule, liquid, powder or aerosol preparations or formulations, or preparations or formulations for oral delivery or inhalation.